I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

AxoGen (AXGN) Prices offering of 2 M share at $21.00

November 16, 2017

AXGN is down -$2.95 or -11.85% after closing at $24.90

Regenerative Medicine Earnings Scorecard - Q3/2017 to date

November 14, 2017

Thirty four (34) as of today ... so far Financial results also known as (AKA) earnings are a ‘scorecard’ of public stem, cell, gene and regenerative therapy's companies.    

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.